NEW YORK (GenomeWeb News) — Pharsight has licensed its public-source type II diabetes meta-database to an undisclosed biotechnology company, the informatics shop said today.
 
The deal is the firs time Pharsight has licensed one of its 20 meta-databases, which compare the “simulated” efficacy and safety of candidate drugs against those of existing drugs, the company said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.